Market revenue in 2023 | USD 2,604.8 million |
Market revenue in 2030 | USD 4,649.7 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Clinical |
Fastest growing segment | Pre-Clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drug Discovery, Pre-Clinical, Clinical |
Key market players worldwide | Icon PLC, Charles River Laboratories International Inc, IQVIA Holdings Inc, GVK Biosciences, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, PAREXEL, Dassault Systemes SE, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, SGS AG, Worldwide Clinical Trials, Wuxi AppTec Co Ltd, Caidya |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to healthcare contract research organization market will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 75.85% in 2023. Horizon Databook has segmented the China healthcare contract research organization market based on drug discovery, pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
The rapid growth of China’s R&D sector has been fueled by a more favorable regulatory environment, which has increased the number of FDA and the National Medical Products Administration (NMPA) drug approvals.
Pharmaceutical companies have shifted toward externalized R&D models, with around half of their pipelines sourced from outside. This trend has been driven by the robust biotech funding environment. In 2019, the U.S. FDA approved 38 chemical New Molecular Entities (NMEs) and 10 new biological products.
The country is implementing an arrays of strategies to improve clinical trials and speed up the drug approval. This takes into account the Chinese population's average wait time of 6 years to receive drugs already approved in Western countries.
Horizon Databook provides a detailed overview of country-level data and insights on the China healthcare contract research organization market , including forecasts for subscribers. This country databook contains high-level insights into China healthcare contract research organization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account